NEW YORK, March 21, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Migralex™, a commercially available over-the-counter medication for treating pain.
As part of the transaction, all assets from Migralex, Inc. will be transferred to Ember Therapeutics, Inc.
“This is our second acquisition this quarter. The addition of a great brand, such as Migralex™, to our pipeline will allow us to provide relief to over 150 million Americans suffering from recurrent pain,” said Joseph Hernandez, Executive Chairman of Ember Therapeutics, Inc. “Furthermore, as Migralex™ is a commercial stage asset, the revenue generated by this product will help further the development of our two Phase 3 ready clinical programs in osteoarthritis and regenerative medicine.”
As a result of over 25 years of research, world renowned neurologist, leading pain expert and founder of the New York Headache Center, Dr. Alexander Mauskop has developed and patented a breakthrough headache medicine that has been clinically proven to be highly effective in relieving most types of pain, including arthritis pain, tension headaches, sinus headaches, stress headaches, menstrual headaches, and various other pains. Dr. Mauskop’s Migralex™ is a patented product and is the strongest combination pain medicine available without a prescription. Its special rapid release formula gives fast acting relief, and is gentle on the stomach. Migralex™ reduces side effects common with other OTC pain relievers. It contains no caffeine, sodium or preservatives, and contains magnesium as a buffering agent.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a pharmaceutical company developing targeted therapies for pain, osteoarthritis, kidney fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has a commercial stage pain product and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.
The Ruth Group Lee Roth (investors) (646) 536-7012 email@example.com